Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.

Zhang, Bing-Chen; Luo, Bang-Yue; Zou, Jun-Jie; Wu, Peng-Yu; Jiang, Jia-Li; Le, Jing-Qing; Zhao, Rui-Rui; Chen, Lu; Shao, Jing-Wei

Zhang, Bing-Chen; Luo, Bang-Yue; Zou, Jun-Jie; Wu, Peng-Yu; Jiang, Jia-Li; Le, Jing-Qing; Zhao, Rui-Rui; Chen, Lu; Shao, Jing-Wei.

Afiliação

Zhang BC; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Luo BY; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Zou JJ; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Wu PY; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Jiang JL; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Le JQ; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Zhao RR; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.
Chen L; Institute of Oceanography, College of Ocean, Minjiang University, Fuzhou 350108, China.
Shao JW; Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, Fujian, China.

ACS Appl Mater Interfaces ; 12(51): 57362-57372, 2020 Dec 23.

Article em En | MEDLINE | ID: mdl-33301289

Assuntos

Sistemas CRISPR-Cas; Carcinoma Hepatocelular/tratamento farmacológico; Neoplasias Hepáticas/tratamento farmacológico; Nanopartículas/química; Dióxido de Silício/química; Sorafenibe/uso terapêutico; Animais; Aptâmeros de Nucleotídeos/química; Aptâmeros de Nucleotídeos/toxicidade; Proteína 9 Associada à CRISPR/genética; Linhagem Celular Tumoral; Portadores de Fármacos/química; Portadores de Fármacos/toxicidade; Liberação Controlada de Fármacos; Molécula de Adesão da Célula Epitelial/química; Receptores ErbB/genética; Receptores ErbB/metabolismo; Edição de Genes; Genes erbB-1; Humanos; Camundongos; Nanopartículas/toxicidade; Poliaminas/química; Poliaminas/toxicidade; Porosidade; Transdução de Sinais/efeitos dos fármacos; Dióxido de Silício/toxicidade

Palavras-chave

CRISPR/Cas9; HCC treatment; drug delivery; gene editing; nanoparticles

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Dióxido de Silício / Nanopartículas / Sistemas CRISPR-Cas / Sorafenibe / Neoplasias Hepáticas Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google